Prospective Multicenter Trial of Early Versus Late Drain Removal After Pancreaticoduodenectomy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03055676 |
Recruitment Status :
Completed
First Posted : February 16, 2017
Last Update Posted : April 24, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pancreaticoduodenectomy Drainage | Other: Early drain removal Other: Late drain removal | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 319 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Prospective Multicenter Trial of Early Versus Late Drain Removal After Pancreaticoduodenectomy |
Study Start Date : | January 2017 |
Actual Primary Completion Date : | March 2020 |
Actual Study Completion Date : | April 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Early drain removal
Removing drain(s) on postoperative day 3 (n = 166)
|
Other: Early drain removal
Removing drain(s) on postoperative day 3 |
Active Comparator: Late drain removal
Removing drain(s) on postoperative day 5 or later (n = 166)
|
Other: Late drain removal
Removing drain(s) on postoperative day 5 or later |
- The sum of grade 2- 4 complications [ Time Frame: Up to postoperative 90 days ]The severity of complication was measured by Clavein Dindo classifications and grade 2- 4 complications always affect the recovery of the patients significantly.However, the death case (grade 5 complication) is rare now for PD in high volume centers. According to our single center study, early drain removal could reduce the rate of grade 2-4 complications by 12% for the patients undergoing major pancreatectomy.
- Intra-abdominal bleeding [ Time Frame: Up to postoperative 90 days ]The International Study Group of Pancreatic Surgery (ISGPS) definition: Blood loss through abdominal drains or nasogastric tube;hematemesis or melena; clinical deterioration of the patient; unexplained hypotension or tachycardia; or laboratory findings such as a decreasing hemoglobin concentration.
- Delayed gastric emptying [ Time Frame: Up to postoperative 90 days ]The International Study Group of Pancreatic Surgery (ISGPS) definition: Inability to return to a standard diet by the end of the first postoperative week with prolonged nasogastric intubation.
- Grade B/C complications [ Time Frame: Up to postoperative 90 days ]The International Study Group of Pancreatic Surgery (ISGPS) definition
- Length of hospital stay (day) [ Time Frame: Up to postoperative 90 days ]Participants will be followed for the duration of hospital stay, an expected average of 2 weeks.
- Comprehensive complication index (CCI) [ Time Frame: Up to postoperative 90 days ]integrates all complications of the Clavien-Dindo classification (CDC) and offers a metric approach to measure morbidity.
- Interventional treatment [ Time Frame: Up to postoperative 90 days ]interventional treatment for any complication.
- Total medical expenses [ Time Frame: Up to postoperative 90 days ]Total medical expenses during hospitalization.
- Any other single intem of grade 2-4 complication [ Time Frame: Up to postoperative 90 days ]Clavein Dindo Classification is adopted.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- PD with or without pylorus preserving;
- Age between 18 and 75 years;
- Drain amylase on POD 1 and 3 less than 5000 U/L;
- Drain output within POD 3 less than 300 ml per day.
Exclusion Criteria:
- Vascular reconstruction using an artificial graft;
- Grade B/ C postoperative bleeding, evident anastomosis leakage within 3 days after surgery;
- Refusale to participate in after signed informed consent.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03055676
China | |
Peking Union Medical College Hospital | |
Beijing, China, 100730 |
Study Chair: | Menghua Dai, M.D. | Peking Union Medical College Hospital |
Responsible Party: | Peking Union Medical College Hospital |
ClinicalTrials.gov Identifier: | NCT03055676 |
Other Study ID Numbers: |
PUMCH-GS05 |
First Posted: | February 16, 2017 Key Record Dates |
Last Update Posted: | April 24, 2020 |
Last Verified: | April 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | After this multicenter randomized clinical trail complete, the results of this study will be submitted to and published in a peer-reviewing journal. Other researchers can assess our article through electronic database, such as Medline/PubMed. |
Pancreaticoduodenectomy Time of drain removal |